US Stock MarketDetailed Quotes
EVAX Evaxion Biotech
- 1.140
- -0.050-4.20%
Close Dec 13 16:00 ET
- 1.100
- -0.040-3.51%
Post 17:58 ET
6.69MMarket Cap-0.41P/E (TTM)
1.220High1.090Low82.29KVolume1.150Open1.190Pre Close95.49KTurnover2.24%Turnover RatioLossP/E (Static)5.87MShares13.61052wk High87.69P/B4.19MFloat Cap1.08052wk Low--Dividend TTM3.67MShs Float250.400Historical High--Div YieldTTM10.92%Amplitude1.080Historical Low1.160Avg Price1Lot Size
Evaxion Biotech Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q3)Sep 30, 2021 | (Q2)Jun 30, 2021 | (Q1)Mar 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 31.36%-17.69M | -17.51%-25.77M | 30.69%-5.19M | -102.87%-8.19M | -76.34%-21.93M | -4.12M | -127.67%-6.3M | -225.14%-7.49M | -36.78%-4.04M | -77.20%-12.44M |
| Net income from continuing operations | 4.51%-22.13M | 5.56%-23.17M | 30.08%-4.77M | -41.49%-5.79M | -63.35%-24.53M | ---8.37M | -30.92%-5.25M | -87.34%-6.82M | -32.07%-4.09M | -34.15%-15.02M |
| Operating gains losses | 28.61%-282K | ---395K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 7.71%615K | 65.99%571K | ---- | ---- | 227.62%344K | ---- | ---- | ---- | ---- | 29.63%105K |
| Deferred tax | 1.40%-984K | -425.26%-998K | ---- | ---- | 90.81%-190K | ---- | ---- | ---- | ---- | -150.55%-2.07M |
| Other non cash items | 356.23%1.36M | 46.57%-530K | -1,271.43%-820K | 86.81%-129K | -824.09%-992K | --54K | -112.79%-138K | -69.30%70K | -292.90%-978K | -4.86%137K |
| Change In working capital | 154.29%1.56M | -332.58%-2.88M | 157.86%427K | -308.96%-2.17M | 475.35%1.24M | --1.84M | -645.78%-906K | -348.48%-738K | 389.94%1.04M | -62.48%215K |
| -Change in receivables | 174.50%1.11M | -179.76%-1.49M | ---- | ---- | 174.49%1.86M | ---- | ---- | ---- | ---- | -642.14%-2.5M |
| -Change in payables and accrued expense | 132.71%455K | -122.20%-1.39M | ---- | ---- | -123.05%-626K | ---- | ---- | ---- | ---- | 198.46%2.72M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 31.36%-17.69M | -17.51%-25.77M | 30.69%-5.19M | -102.87%-8.19M | -76.34%-21.93M | ---4.12M | -127.67%-6.3M | -225.14%-7.49M | -36.78%-4.04M | -77.20%-12.44M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 65.30%-93K | 79.85%-268K | 84.44%-77K | 51.38%-159K | -238.42%-1.33M | -177K | -6,520.00%-331K | -1,000.00%-495K | -303.70%-327K | -477.94%-393K |
| Net PPE purchase and sale | 70.21%-87K | 77.54%-292K | 83.73%-83K | 35.82%-181K | -263.13%-1.3M | ---176K | -16,500.00%-332K | -5,000.00%-510K | -340.63%-282K | -426.47%-358K |
| Net intangibles purchase and sale | --0 | --0 | ---- | --0 | -71.43%-60K | --0 | --0 | --0 | ---60K | ---35K |
| Net investment purchase and sale | -125.00%-6K | -20.00%24K | -60.00%6K | 46.67%22K | --30K | ---1K | 133.33%1K | --15K | 188.24%15K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 65.30%-93K | 79.85%-268K | 84.44%-77K | 51.38%-159K | -238.42%-1.33M | ---177K | -6,520.00%-331K | -1,000.00%-495K | -303.70%-327K | -477.94%-393K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 36.14%10.69M | -84.23%7.85M | -757.14%-300K | -69.36%7.74M | 464.87%49.81M | 24.65M | -101.00%-65K | -94.44%-35K | 140,388.89%25.25M | -7.27%8.82M |
| Net issuance payments of debt | -108.51%-632K | 2,669.20%7.43M | -205.71%-107K | 18,095.35%7.74M | -290.54%-289K | ---144K | -252.63%-67K | -94.44%-35K | -138.89%-43K | -193.67%-74K |
| Net common stock issuance | 2,042.06%9.17M | -99.21%428K | --28K | --0 | 497.12%53.85M | --25.95M | -99.98%1K | --0 | --27.9M | -4.48%9.02M |
| Proceeds from stock option exercised by employees | --2.59M | --0 | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
| Net other financing activities | ---432K | ---- | ---- | ---- | -2,837.50%-3.76M | ---1.16M | --1K | --0 | ---2.61M | -884.62%-128K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 36.14%10.69M | -84.23%7.85M | -757.14%-300K | -69.36%7.74M | 464.87%49.81M | --24.65M | -101.00%-65K | -94.44%-35K | 140,388.89%25.25M | -7.27%8.82M |
| Net cash flow | ||||||||||
| Beginning cash position | -59.01%13.18M | 451.35%32.17M | 16.52%31.41M | 451.35%32.17M | -38.97%5.83M | --11.94M | 360.20%18.8M | 324.82%26.96M | -38.97%5.83M | 28.60%9.56M |
| Current changes in cash | 61.00%-7.09M | -168.53%-18.19M | 30.57%-5.57M | -102.91%-607K | 761.40%26.54M | --20.36M | -280.40%-6.69M | -238.88%-8.02M | 785.14%20.89M | -265.76%-4.01M |
| Effect of exchange rate changes | 35.94%-508K | -277.62%-793K | -327.54%-590K | -164.94%-150K | -172.92%-210K | ---139K | -302.47%-164K | -230.19%-138K | 240.00%231K | 197.63%288K |
| End cash Position | -57.65%5.58M | -59.01%13.18M | 34.33%25.25M | 16.52%31.41M | 451.35%32.17M | --32.17M | 51.67%11.94M | 360.20%18.8M | 324.82%26.96M | -38.97%5.83M |
| Free cash flow | 31.80%-17.78M | -11.90%-26.07M | 34.07%-5.27M | -91.16%-8.37M | -81.54%-23.29M | ---4.29M | -139.50%-6.63M | -240.63%-8M | -45.22%-4.38M | -81.05%-12.83M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data